

## 7. References

- Andronis L, Oppong RA, Manga N, Senanayake E, Gopal S, Charman S, et al. Is the Venner-PneuX Endotracheal Tube System a Cost-Effective Option for Post Cardiac Surgery Care? *Ann Thorac Surg.* Sep. 2018;106(3):757–63.
- Antimicrobial resistance in the EU/EEA (EARS-Net) - Annual epidemiological report for 2021 [Internet]. European Centre for Disease Prevention and Control. 2022 [cited 03Dec. 2022]. Available at: <https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-resistance-europe-2021>
- Balandin B, Ballesteros D, Ruiz de Luna R, López-Vergara L, Pintado V, Sancho-González M, et al. Multicenter study of ceftolozane/tazobactam for treatment of *Pseudomonas aeruginosa* infections in critically ill patients. *Int J Antimicrob Agents.* Mar. 2021;57(3):106270.
- Bartsch SM, McKinnell JA, Mueller LE, Miller LG, Gohil SK, Huang SS, et al. Potential economic burden of carbapenem-resistant Enterobacteriaceae (CRE) in the United States. *Clin Microbiol Infect.* Jan. 2017;23(1):48.e9-48.e16.
- Cabot G, Bruchmann S, Mulet X, Zamorano L, Moyà B, Juan C, et al. *Pseudomonas aeruginosa* Ceftolozane-Tazobactam Resistance Development Requires Multiple Mutations Leading to Overexpression and Structural Modification of AmpC. *Antimicrob Agents Chemother.* Jun. 2014;58(6):3091–9.
- Candel FJ, Santerre Henriksen A, Longshaw C, Yamano Y, Oliver A. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection. *Clin Microbiol Infect.* Mar. 2022;28(3):447.e1-447.e6.
- CRE | HAI | CDC [Internet]. 2021 [cited 03Dec. 2022]. Available at: <https://www.cdc.gov/hai/organisms/cre/index.html>

- Dick AW, Perencevich EN, Pogorzelska-Maziarz M, Zwanziger J, Larson EL, Stone PW. A decade of investment in infection prevention: A cost-effectiveness analysis. *Am J Infect Control*. Jan. 2015;43(1):4–9.
- ESBL-producing Enterobacterales | HAI | CDC [Internet]. 2021 [cited 03Dec. 2022]. Available at: <https://www.cdc.gov/hai/organisms/ESBL.html>
- Gallagher JC, Satlin MJ, Elabor A, Saraiya N, McCreary EK, Molnar E, et al. Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant *Pseudomonas aeruginosa* Infections: A Multicenter Study. *Open Forum Infect Dis*. 01Nov. 2018;5(11):ofy280.
- Hosein FS, Roberts DJ, Turin TC, Zygun D, Ghali WA, Stelfox HT. A meta-analysis to derive literature-based benchmarks for readmission and hospital mortality after patient discharge from intensive care. *Crit Care*. Dec. 2014;18(6):715.
- IDSA. IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. 2022.
- JAID/JSC 感染症治療ガイド・ガイドライン作成委員会. JAID/JSC 感染症治療ガイド 2019. (日本感染症学会・日本化学療法学会).
- Karlowsky JA, Hackel MA, Takemura M, Yamano Y, Echols R, Sahm DF. In Vitro Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019. *Antimicrob Agents Chemother*. 15Feb. 2022;66(2):e01990-21.
- Kollef MH, Nováček M, Kivistik Ü, Réa-Neto Á, Shime N, Martin-Loeches I, et al. Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. *Lancet Infect Dis*. Dec. 2019;19(12):1299–311.
- Kongnakorn T, Eckmann C, Bassetti M, Tichy E, Di Virgilio R, Baillon-Plot N, et al. Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical

treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI). *Antimicrob Resist Infect Control*. Dec. 2019;8(1):204.

Lodise T, Yang J, Puzniak LA, Dillon R, Kollef M. Healthcare Resource Utilization of Ceftolozane/Tazobactam Versus Meropenem for Ventilated Nosocomial Pneumonia from the Randomized, Controlled, Double-Blind ASPECT-NP Trial. *Infect Dis Ther*. Dec. 2020;9(4):953–66.

MacKinnon MC, Sargeant JM, Pearl DL, Reid-Smith RJ, Carson CA, Parmley EJ, et al. Evaluation of the health and healthcare system burden due to antimicrobial-resistant *Escherichia coli* infections in humans: a systematic review and meta-analysis. *Antimicrob Resist Infect Control*. Dec. 2020;9(1):200.

MSD 株式会社. ザバクサ配合点滴静注用. 添付文書. 2021.

MSD 株式会社. ザバクサ配合点滴静注用\_審査報告書. 2019.

Naik J, Puzniak L, Critchlow S, Elsea D, Dillon RJ, Yang J. Cost Effectiveness of Ceftolozane/Tazobactam Compared with Meropenem for the Treatment of Patients with Ventilated Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia. *Infect Dis Ther*. Jun. 2021;10(2):939–54.

Naylor NR, Pouwels KB, Hope R, Green N, Henderson KL, Knight GM, et al. The health and cost burden of antibiotic resistant and susceptible *Escherichia coli* bacteraemia in the English hospital setting: A national retrospective cohort study. Leekha S,ed. *PLOS ONE*. 10Sep. 2019;14(9):e0221944.

Paul M, Carrara E, Retamar P, Tängdén T, Bitterman R, Bonomo RA, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). *Clin Microbiol Infect*. Apr.

2022;28(4):521–47.

Saunders R, Geogopoulos D. Evaluating the Cost-Effectiveness of Proportional-Assist

Ventilation Plus vs. Pressure Support Ventilation in the Intensive Care Unit in Two

Countries. *Front Public Health*. 06Jun. 2018;6:168.

Simon MS, Sfeir MM, Calfee DP, Satlin MJ. Cost-Effectiveness of Ceftazidime-Avibactam

for Treatment of Carbapenem-Resistant Enterobacteriaceae Bacteremia and

Pneumonia. *Antimicrob Agents Chemother*. Dec. 2019;63(12):e00897-19.

Solomkin J, Hershberger E, Miller B, Popejoy M, Friedland I, Steenbergen J, et al.

Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal

Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-

Blind, Phase 3 Trial (ASPECT-cIAI). *Clin Infect Dis*. 15May. 2015;60(10):1462–71.

Soontaros S, Leelakanok N. Association between carbapenem-resistant Enterobacteriaceae

and death: A systematic review and meta-analysis. *Am J Infect Control*. Oct.

2019;47(10):1200–12.

Tacconelli E and Magrini N. GLOBAL PRIORITY LIST OF ANTIBIOTIC-RESISTANT

BACTERIA TO GUIDE RESEARCH, DISCOVERY, AND DEVELOPMENT OF

NEW ANTIBIOTICS. 2017.

Tichy E, Torres A, Bassetti M, Kongnakorn T, Di Virgilio R, Irani P, et al. Cost-effectiveness

Comparison of Ceftazidime/Avibactam Versus Meropenem in the Empirical

Treatment of Hospital-acquired Pneumonia, Including Ventilator-associated

Pneumonia, in Italy. *Clin Ther*. May. 2020;42(5):802–17.

Wagenlehner FM, Umeh O, Steenbergen J, Yuan G, Darouiche RO. Ceftolozane-tazobactam

compared with levofloxacin in the treatment of complicated urinary-tract infections,

including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI).

*The Lancet*. May. 2015;385(9981):1949–56.

令和 3 年簡易生命表の概況 | 厚生労働省 [Internet]. [cited 02Dec. 2022]. Available at:

<https://www.mhlw.go.jp/toukei/saikin/hw/life/life21/index.html>

令和 4 年度診療報酬改定について [Internet]. [cited 02Dec. 2022]. Available at:

[https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000188411\\_00037.html](https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000188411_00037.html)

国立保健医療科学院 保健医療経済評価研究センター. 中央社会保険医療協議会における 費用対効果評価の分析ガイドライン第 2 版. 2019.

感染症法に基づくカルバペネム耐性腸内細菌科細菌感染症の届出状況 2019 年

[Internet]. [cited 02Dec. 2022]. Available at: <https://www.niid.go.jp/niid/ja/cre-m/cre-idwrs/10319-cre-210423.html>

日医工株式会社. アミカシン硫酸塩注射用. 添付文書. 2011.

薬価基準収載品目リスト及び後発医薬品に関する情報について（令和 4 年 11 月 16

日適用） | 厚生労働省 [Internet]. [cited 02Dec. 2022]. Available at:

<https://www.mhlw.go.jp/topics/2022/04/tp20220401-01.html>